May 2, 2003
Warburg Pincus invests $31 million in Rib-X Pharmaceuticals Inc., which is raising funds to build a stronger arsenal of anti-infective drugs to battle drug-resistant bacteria (“super-bugs”).
Willkie advised Warburg Pincus on its $31 million cash investment in Rib-X Pharmaceuticals Inc., which is raising funds to build a stronger arsenal of anti-infective drugs to battle drug-resistant bacteria (“super-bugs”). Rib-X raised $63.5 million in this second round of venture capital financing, bringing the total to $73.5 million for the 2-year-old startup. The May 2 Daily Deal notes partner Peter Jakes for his work on the transaction.